Investigational HIV integrase inhibitors in phase I and phase II clinical trials

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens

(2016) F Raffi et al.   HIV MEDICINE

The promise and pitfalls of long-acting injectable agents for HIV prevention

(2016) Raphael J. Landovitz et al.   Current Opinion in HIV and AIDS

Targeting Virus-host Interactions of HIV Replication

(2015) Caroline Weydert et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Cabotegravir. HIV integrase inhibitor, Anti-HIV agent

(2015)   DRUGS OF THE FUTURE

Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection

(2015) Tae Eun Park et al.   Expert Review of Anti-Infective Therapy

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

(2015) J. Radzio et al.   Science Translational Medicine

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

(2015) Chasity D. Andrews et al.   Science Translational Medicine

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

(2015) Melinda J. Reese et al.   XENOBIOTICA

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

(2015) Thibault Mesplède et al.   Viruses-Basel

Cabotegravir long-acting for HIV-1 prevention

(2015) Chasity D. Andrews et al.   Current Opinion in HIV and AIDS

Formulation and pharmacology of long-acting cabotegravir

(2015) Christine Trezza et al.   Current Opinion in HIV and AIDS

Integrase strand transfer inhibitors in the management of HIV-positive individuals

(2014) Thibault Mesplède et al.   ANNALS OF MEDICINE

Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

(2014) Craig Fenwick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1

(2014) Lee D. Fader et al.   ACS Medicinal Chemistry Letters

Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences

(2014) Jay A. Grobler et al.   Current Opinion in Virology

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

(2013) Susan L. Ford et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Allosteric inhibition of HIV-1 integrase activity

(2013) Alan Engelman et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

(2013) W. Spreen et al.   HIV CLINICAL TRIALS

Differential Sensitivities of Retroviruses to Integrase Strand Transfer Inhibitors

(2011) Y. Koh et al.   JOURNAL OF VIROLOGY

Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication

(2010) Frauke Christ et al.   Nature Chemical Biology

Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir

(2009) G. B. Beck-Engeser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA